financetom
Business
financetom
/
Business
/
Paramount Global, Nielsen sign new partnership, ending dispute
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Paramount Global, Nielsen sign new partnership, ending dispute
Feb 3, 2025 11:19 AM

Feb 3 (Reuters) - Media giant Paramount Global ( PARAA )

and Nielsen have signed a new deal that would see the research

firm provide measurement and analytics services across the CBS

parent company's platforms, ending a long-running dispute.

The multi-year deal, effective immediately, includes

measurement for Paramount's national and local broadcast, cable

networks, and streaming on Paramount+ and Pluto TV.

Paramount has also licensed new Nielsen services as part of

the agreement including Advanced Audiences, ad-supported

streaming platform ratings to help form advertising, programming

and licensing strategies.

"We are thrilled to resume our partnership with Paramount,"

said Karthik Rao, Nielsen CEO, adding that the deal will be a

"win for everyone: Nielsen, Paramount and all of our joint

advertising partners."

The media company had ended its partnership with Nielsen

last year, deciding not to renew a contract that expired on

Sept. 30, according to a Variety report.

The companies were in renewal discussions for months, the

report said, but could not agree on pricing terms. In the

interim, Paramount used a different measurement firm, VideoAmp,

a rival to Nielsen.

"This really is not about affordability. It's about getting

the value we need for what we pay," Paramount Global ( PARAA ) co-CEO

George Cheeks had said during the company's last earnings call

in November. "... we wouldn't want the Nielsen fee for certain

networks to be greater than the ad revenue those networks

actually generate."

Music's Grammy Awards was broadcast live on CBS on Sunday

and the viewership for Golden Globes on CBS, Paramount+ and the

CBS app averaged 10.1 million people in January, according to

VideoAmp.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Consumer lender Ally Financial to sell credit card business to CardWorks
Consumer lender Ally Financial to sell credit card business to CardWorks
Jan 22, 2025
Jan 22 (Reuters) - Consumer lender Ally Financial ( ALLY ) has agreed to sell its credit card business to credit and payments firm CardWorks, the companies said on Wednesday. ...
ImmunoPrecise Antibodies Says New Class of GLP-1 Therapies Developed Using AI; Shares Jump
ImmunoPrecise Antibodies Says New Class of GLP-1 Therapies Developed Using AI; Shares Jump
Jan 22, 2025
07:44 AM EST, 01/22/2025 (MT Newswires) -- ImmunoPrecise Antibodies' ( IPA ) shares climbed by nearly 80% in premarket trading Wednesday after the company said it has developed a new class of GLP-1 therapies to treat diabetes using its LENS AI artificial intelligence platform. The company said the new therapies were developed through the platform's rapid sequence generation process. The...
Ally Financial to Sell Credit Card Business to CardWorks
Ally Financial to Sell Credit Card Business to CardWorks
Jan 22, 2025
07:43 AM EST, 01/22/2025 (MT Newswires) -- Ally Financial ( ALLY ) said Wednesday it has agreed to sell its credit card business to CardWorks. Financial terms of the deal were not disclosed. The deal is expected to allow Ally to be more focused on its core businesses. Meanwhile, it is expected to enhance CardWorks' position as a credit card...
Oncolytics Biotech to Present New Efficacy and Safety Data at ASCO Symposium
Oncolytics Biotech to Present New Efficacy and Safety Data at ASCO Symposium
Jan 22, 2025
07:42 AM EST, 01/22/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Wednesday said its pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in relapsed anal cancer patients. The complete response observed previously also continued beyond the 12 months initially reported. Pelareorep-based therapy also continues to show a strong safety profile with a new chemotherapy regimen...
Copyright 2023-2026 - www.financetom.com All Rights Reserved